MedTrace Logo

Evaluate Safety, Tolerability, Pharmacokinetics and Anti-tumor Activity of AZD3759

NCT03360929 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2022-11-25

No results posted yet for this study

Summary

This is a multi-center, open-label, dose escalation and phase I/II study, consisting of dose escalation in Part A and phase II study in Part B.

Conditions

  • Non Small Cell Lung Cancer

Interventions

DRUG

AZD3759

Strength: 50mg/tablet, 100mg/tablet Dosage and administration: Twice daily administration under fasting state.

Sponsors & Collaborators

  • Tigermed Consulting Co., Ltd

    collaborator INDUSTRY

  • LYZZ Alpha Holding Ltd

    lead INDUSTRY

Principal Investigators

  • Yilong Wu, Professor · Guangdong Provincial People's Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-10-30
Primary Completion
2020-11-13
Completion
2020-11-13

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03360929 on ClinicalTrials.gov